Trial Results, Stock Splits, Share Repurchases, New Appointments, and Completed Acquisitions - Research Report on Incyte, Novo

    Trial Results, Stock Splits, Share Repurchases, New Appointments, and
 Completed Acquisitions - Research Report on Incyte, Novo Nordisk, Thoratec,
                        Alere, and Kindred Healthcare

PR Newswire

NEW YORK, December 18, 2013

NEW YORK, December 18, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Incyte
Corporation (NASDAQ: INCY), Novo Nordisk A/S (NYSE: NVO), Thoratec Corp.
(NASDAQ: THOR), Alere Inc. (NYSE: ALR), and Kindred Healthcare Inc. (NYSE:
KND). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

Incyte Corporation Research Report

On December 9, 2013, Incyte Corporation (Incyte) presented the results of an
interim analysis from a 12-week open-label, dose-escalation Phase II clinical
trial involving more than 85 patients with intermediate or high-risk
myelofibrosis (MF) for its proprietary oral JAK1 inhibitor, INCB39110, at the
2013 American Society of Hematology (ASH) Annual Meeting in New Orleans.
Richard S. Levy, M.D., Incyte's Executive Vice President and Chief Drug
Development and Medical Officer, stated, "With the interim analysis of this
trial combined with data from two other proof-of-concept trials in rheumatoid
arthritis and psoriasis, we have a better understanding of JAK1 as a disease
target, and we're using this knowledge to focus the development of our broad
portfolio of JAK1 inhibitors." Levy continued, "We are taking INCB39110, our
most advanced JAK1 inhibitor, forward initially in solid tumors, starting with
combinations that may not be as well-tolerated with a JAK1/JAK2 inhibitor as a
result of the potential myelosuppressive effect of JAK2 inhibition." The Full
Research Report on Incyte Corporation - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.AnalystsCorner.com/r/full_research_report/076e_INCY

Novo Nordisk A/S Research Report

On December 10, 2013, Novo Nordisk A/S (Novo Nordisk) announced that its Board
of Directors has approved a stock split of the Novo Nordisk B shares listed on
NASDAQ OMX Copenhagen and of the American Depositary Receipts (ADRs) listed on
New York Stock Exchange (NYSE). Novo Nordisk reported that the trading unit of
the Novo Nordisk B shares listed on the stock exchange in Copenhagen will be
changed from DKK 1 to DKK 0.20, while the ratio of B shares to ADRs listed on
NYSE will remain 1:1. Further, the Company stated that the changes in the
trading units will be effective on January 2, 2014 for the Novo Nordisk B
shares and on January 9, 2014 for the ADRs. The Full Research Report on Novo
Nordisk A/S - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/fee1_NVO

Thoratec Corp. Research Report

On December 9, 2013, Thoratec Corp. (Thoratec) announced that its Board of
Directors has authorized a $200-million share repurchase program for its
common stock, effective through the end of 2015. According to Thoratec, its
previous share repurchase authorization is slated to expire at the end of
2013. Commenting on the repurchase authorization, Gary F. Burbach, Thoratec
President and CEO, said, "This authorization reflects our strong financial
position and commitment to a disciplined capital allocation strategy, along
with continued confidence in our long-term growth opportunities. Funding our
internal growth initiatives and pursuing attractive business development
opportunities remain our top priorities, although this authorization provides
the flexibility to also allocate capital to share repurchases in a measured
and opportunistic fashion over time." The Full Research Report on Thoratec
Corp. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/1bee_THOR

Alere Inc. Research Report

On December 12, 2013, Alere Inc. (Alere) announced the appointment of Regina
M. Benjamin, MD, MBA to its Board of Directors, effective immediately.
Commenting on the appointment, Ron Zwanziger, Alere Chairman and CEO, said,
"Having served as America's Doctor, Regina brings invaluable experience and
insights, as well as a longstanding commitment to improving health care
outcomes - particularly for underserved populations. Her leadership in public
health aligns perfectly with Alere's development of breakthrough technologies
that enhance patient care." The Full Research Report on Alere Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5da1_ALR

Kindred Healthcare Inc. Research Report

On December 12, 2013, Kindred Healthcare Inc. (Kindred Healthcare) announced
that its subsidiaries have successfully completed the acquisition of real
estate associated with seven nursing centers that it currently leases from
HCP, Inc. and its affiliates (HCP) for approximately $61 million. The Company
had previously agreed to acquire the real estate associated with two other
nursing centers from HCP and expects to close the acquisition of those two
properties in Q1 2014. Further, it anticipates the transactions with HCP to be
slightly accretive to its 2014 earnings. Paul J. Diaz, CEO of Kindred
Healthcare, commented, "Purchasing the real estate of these nursing centers
allows us to improve our capital structure as we enter the growth phase of our
strategic plan." Diaz added, "We continue to explore opportunities to invest
in our Integrated Care Markets, and our growing Care Management business and
Kindred at Home." The Full Research Report on Kindred Healthcare Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/ab58_KND

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com/

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.